146 related articles for article (PubMed ID: 21358826)
21. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
[TBL] [Abstract][Full Text] [Related]
22. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US.
Brooks RA; Newman PA; Duan N; Ortiz DJ
AIDS Care; 2007 Jan; 19(1):52-8. PubMed ID: 17129857
[TBL] [Abstract][Full Text] [Related]
23. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
[TBL] [Abstract][Full Text] [Related]
24. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
Newman PA; Daley A; Halpenny R; Loutfy M
Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829
[TBL] [Abstract][Full Text] [Related]
25. Willingness to volunteer in a Phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania.
Tarimo EA; Thorson A; Bakari M; Mwami J; Sandström E; Kulane A
Glob Health Action; 2009 Aug; 2():. PubMed ID: 20027266
[TBL] [Abstract][Full Text] [Related]
26. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
[TBL] [Abstract][Full Text] [Related]
27. Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya.
Farquhar C; John-Stewart GC; John FN; Kabura MN; Kiarie JN
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):491-5. PubMed ID: 16796522
[TBL] [Abstract][Full Text] [Related]
28. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
29. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial.
Sheon AR; Wagner L; McElrath MJ; Keefer MC; Zimmerman E; Israel H; Berger D; Fast P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):519-26. PubMed ID: 9859967
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and risk factors associated with HIV-1 infection among people who inject drugs in Dar es Salaam, Tanzania: a sign of successful intervention?
Likindikoki SL; Mmbaga EJ; Leyna GH; Moen K; Makyao N; Mizinduko M; Mwijage AI; Faini D; Leshabari MT; Meyrowitsch DW
Harm Reduct J; 2020 Mar; 17(1):18. PubMed ID: 32209110
[TBL] [Abstract][Full Text] [Related]
31. Dropouts in a long-term follow-up study involving voluntary counseling and HIV testing: experience from a cohort of police officers in Dar Es Salaam, Tanzania.
Mugusi F; Josiah R; Moshi A; Chale S; Bakari M; Aris E; Magao P; Pallangyo N; Sandstrom E; Biberfeld G; Mhalu F; Pallangyo K
J Acquir Immune Defic Syndr; 2002 May; 30(1):119-23. PubMed ID: 12048372
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.
Markowitz LE; Sirisopana N; Charonwatanachokchai A; Julvanichpong W; Siraprapasiri T; Palanuvej T; Siriwongrangsun P; Tungsakul V; Pumratana K; Chitwarakorn A; Michael RA; Brown AE
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(5):488-94. PubMed ID: 10225232
[TBL] [Abstract][Full Text] [Related]
33. Using pharmacists and drugstore workers as sexual healthcare givers: a qualitative study of men who have sex with men in Dar es Salaam, Tanzania.
Agardh C; Weije F; Agardh A; Nyoni J; Ross MW; Kashiha J; Larsson M
Glob Health Action; 2017; 10(1):1389181. PubMed ID: 29072110
[TBL] [Abstract][Full Text] [Related]
34. Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country.
Lucero MC; Diaz-Brito V; Murillo BT; Carretero SC; Sala M; Casadesús C; Conde MS; Jimenez JL; Pich J; Arnaiz JA; Leon A; Perez I; Muñoz-Fernández MÁ; Gatell JM; Plana M; Esteban M; Bernaldo de Quiros JC; Garcia F;
AIDS Patient Care STDS; 2012 Jul; 26(7):379-82. PubMed ID: 22694172
[No Abstract] [Full Text] [Related]
35. Evidence of a substantial decline in prevalence of HIV-1 infection among pregnant women: data from 1995 to 2003 in Dar es Salaam, Tanzania.
Urassa W; Kaaya S; Mwakagile D; O'Brien M; Antelman G; Hunter D; Fawzi W; Msamanga G
Scand J Public Health; 2006; 34(3):272-8. PubMed ID: 16754585
[TBL] [Abstract][Full Text] [Related]
36. Predictors of AIDS knowledge, condom use and high-risk sexual behaviour among women in Dar-es-Salaam, Tanzania.
Kapiga SH; Lwihula GK; Shao JF; Hunter DJ
Int J STD AIDS; 1995; 6(3):175-83. PubMed ID: 7647120
[TBL] [Abstract][Full Text] [Related]
37. Who will enroll? Predicting participation in a phase II AIDS vaccine trial.
Halpern SD; Metzger DS; Berlin JA; Ubel PA
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):281-8. PubMed ID: 11464149
[TBL] [Abstract][Full Text] [Related]
38. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and geographic distribution of HIV-positive women diagnosed with cervical cancer in Dar es Salaam, Tanzania.
Lovgren K; Soliman AS; Ngoma T; Kahesa C; Meza J
Int J STD AIDS; 2016 Oct; 27(12):1049-1056. PubMed ID: 26464500
[TBL] [Abstract][Full Text] [Related]
40. Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.
Ellman TM; Hawkins K; Benitez J; Negron R; Chang S; Palmer S; Robertson V; Chiasson MA; Sobieszczyk ME
Vaccine; 2015 Nov; 33(48):6809-15. PubMed ID: 26458799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
